{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=36", "query": { "condition": "Cancer", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 50350, "total_pages": 5035, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T21:07:20.305Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00403130", "title": "Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Albert Fisher", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 31, "start_date": "2006-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2019-02-20", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00403130" }, { "nct_id": "NCT01206530", "title": "FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer", "Colon Cancer", "Metastasis", "Adenocarcinoma" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-09", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01206530" }, { "nct_id": "NCT03410030", "title": "Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreas Cancer", "Pancreatic Adenocarcinoma Resectable", "Pancreatic Ductal Adenocarcinoma", "Pancreas Metastases" ], "interventions": [ { "name": "High Dose Ascorbic Acid 25 g/m^2", "type": "DRUG" }, { "name": "Nanoparticle Paclitaxel protein bound 125mg/m^2", "type": "DRUG" }, { "name": "Cisplatin 25mg/m^2", "type": "DRUG" }, { "name": "Gemcitabine 1000mg/m^2", "type": "DRUG" }, { "name": "High Dose Ascorbic Acid 37.5 g/m^2", "type": "DRUG" }, { "name": "High Dose Ascorbic Acid 56.25 g/m^2", "type": "DRUG" }, { "name": "High Dose Ascorbic Acid 75 g/m^2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-12-15", "completion_date": "2023-09-06", "has_results": true, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03410030" }, { "nct_id": "NCT01495130", "title": "Transrectal Ultrasound (TRUS) in Finding Tumors During Robotic-Assisted Laparoscopic Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "ultrasound imaging", "type": "PROCEDURE" }, { "name": "robot-assisted laparoscopic surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 11, "start_date": "2011-10", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2014-01-29", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495130" }, { "nct_id": "NCT02672865", "title": "Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Malignant Neoplasm", "Gastric Cancer" ], "interventions": [ { "name": "Hyperthermic Intraperitoneal Chemotherapy (HIPEC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2016-02-02", "completion_date": "2018-10-03", "has_results": false, "last_update_posted_date": "2019-04-12", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02672865" }, { "nct_id": "NCT00077467", "title": "Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Promyelocytic Leukemia (M3)", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 36, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077467" }, { "nct_id": "NCT04509700", "title": "Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Malignancies" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" }, { "name": "parsaclisib + itacitinib", "type": "DRUG" }, { "name": "parsaclisib + ruxolitinib", "type": "DRUG" }, { "name": "parsaclisib + ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2020-08-03", "completion_date": "2026-11-05", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04509700" }, { "nct_id": "NCT00004107", "title": "Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "indium In 111 monoclonal antibody MN-14", "type": "RADIATION" }, { "name": "yttrium Y 90 epratuzumab", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 18, "start_date": "1998-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-06-22", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 4, "location_summary": "Belleville, New Jersey • Livingston, New Jersey • Paterson, New Jersey + 1 more", "locations": [ { "city": "Belleville", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "Paterson", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004107" }, { "nct_id": "NCT01647711", "title": "A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Dose escalation followed by treatment with MTD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2012-07", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-01-31", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 2, "location_summary": "Aurora, Colorado • Boston, Massachusetts", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01647711" }, { "nct_id": "NCT01838434", "title": "Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2013-10-17", "completion_date": "2017-05-01", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-28T21:07:20.305Z", "location_count": 4, "location_summary": "Chicago, Illinois • St Louis, Missouri • Buffalo, New York + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01838434" } ] }